Watch BCYC. Know when insiders buy.
One email the day a filing lands. Free.
BCYC
BICYCLE THERAPEUTICS PLC
4.18
−0.12 −2.79%
USD · close Sep 8
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
31
FLAG · shorts 31
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $125.6MP/E —DIV YIELD —FCF YIELD -165.85%REV TTM $61.2M +217.4%NET INCOME −$190.4MNET CASH $479.1M52W 3.86 – 8.87SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $629K | −78.5% | — | −$54.6M | −$50.3M | — | -0.72 | −$49.6M | $265K | −$49.9M | Jul 30 |
| Q1 2026 · Mar 31 | $887K | −91.1% | — | −$65.5M | −$60.8M | — | -0.87 | −$65.9M | $713K | −$66.6M | Jul 30 |
| Q4 2025 · Dec 31derived | $48M | +1193.3% | — | −$24.7M | −$20.2M | — | -0.29 | −$19.3M | $574K | −$19.9M | Jul 30 |
| Q3 2025 · Sep 30 | $11.7M | +338.5% | — | −$65.6M | −$59.1M | — | -0.85 | −$71.2M | $674K | −$71.8M | Oct 30 |
| Q2 2025 · Jun 30 | $2.9M | −68.8% | — | −$86.6M | −$79M | — | -1.14 | −$72.8M | $498K | −$73.3M | Jul 30 |
| Q1 2025 · Mar 31 | $10M | −48.9% | — | −$70.2M | −$60.8M | — | -0.88 | −$86.4M | $604K | −$87M | Jul 30 |
| Q4 2024 · Dec 31derived | $3.7M | −86.3% | — | −$67.7M | −$51.9M | — | -0.75 | −$9.4M | $368K | −$9.8M | Mar 17 |
| Q3 2024 · Sep 30 | $2.7M | −50.0% | — | −$63.8M | −$50.8M | — | -0.74 | −$39.8M | $435K | −$40.3M | Oct 30 |
| Q2 2024 · Jun 30 | $9.4M | — | — | −$46.6M | −$39.8M | — | -0.77 | −$44.6M | $420K | −$45M | Oct 30 |
| Q1 2024 · Mar 31 | $19.5M | — | — | −$31.7M | −$26.6M | — | -0.62 | −$70.9M | $12K | −$70.9M | Oct 30 |
| Q4 2023 · Dec 31derived | $27M | — | — | −$54.2M | −$49.1M | — | -1.13 | −$47.3M | $51K | −$47.3M | Mar 17 |
| Q3 2023 · Sep 30 | $5.4M | — | — | −$50.8M | −$49.9M | — | -1.26 | −$1M | $502K | −$1.5M | Oct 31 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $72.6M | — | −$247.1M | −$219M | -301.7% | -3.16 | −$249.7M | $2.4M | −$252M | — | — |
| FY2024 · to Dec 31 | $35.3M | — | −$209.9M | −$169M | -479.2% | -2.90 | −$164.7M | $1.2M | −$166M | — | — |
| FY2023 · to Dec 31 | $27M | — | −$189.9M | −$180.7M | -669.7% | -5.08 | −$60.6M | $2.9M | −$63.6M | — | — |
| FY2022 · to Dec 31 | $14.5M | — | −$116.7M | −$112.7M | -779.3% | -3.80 | −$86.1M | $19M | −$105.1M | — | — |
| FY2021 · to Dec 31 | $11.7M | — | −$65.6M | −$66.8M | -571.2% | -2.67 | −$14.8M | $2M | −$16.8M | — | — |
| FY2020 · to Dec 31 | $10.4M | — | −$52M | −$51M | -491.0% | -2.66 | −$17.8M | $1.2M | −$19M | — | — |
Every number comes from BICYCLE THERAPEUTICS PLC's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.